These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37722688)

  • 1. Gardnerella Vaginolysin Potentiates Glycan Molecular Mimicry by Neisseria gonorrhoeae.
    Morrill SR; Saha S; Varki AP; Lewis WG; Ram S; Lewis AL
    J Infect Dis; 2023 Nov; 228(11):1610-1620. PubMed ID: 37722688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tract.
    Lewis LA; Gulati S; Burrowes E; Zheng B; Ram S; Rice PA
    mBio; 2015 Feb; 6(1):. PubMed ID: 25650401
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Cardenas AJ; Thomas KS; Broden MW; Ferraro NJ; Pires MM; John CM; Jarvis GA; Criss AK
    mBio; 2024 May; 15(5):e0011924. PubMed ID: 38587424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol-Dependent Cytolysins Produced by Vaginal Bacteria: Certainties and Controversies.
    Pleckaityte M
    Front Cell Infect Microbiol; 2019; 9():452. PubMed ID: 31998661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Lst Sialyltransferase of Neisseria gonorrhoeae Can Transfer Keto-Deoxyoctanoate as the Terminal Sugar of Lipooligosaccharide: a Glyco-Achilles Heel That Provides a New Strategy for Vaccines to Prevent Gonorrhea.
    Jen FE; Ketterer MR; Semchenko EA; Day CJ; Seib KL; Apicella MA; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33758087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Sialylation Site on Neisseria gonorrhoeae Lipooligosaccharide Links Heptose II Lactose Expression with Pathogenicity.
    Ram S; Gulati S; Lewis LA; Chakraborti S; Zheng B; DeOliveira RB; Reed GW; Cox AD; Li J; St Michael F; Stupak J; Su XH; Saha S; Landig CS; Varki A; Rice PA
    Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29844237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase variable colony variants are conserved across
    Garcia EM; Klimowicz AK; Edupuganti L; Topf MA; Bhide SR; Slusser DJ; Leib SM; Coddington CL; Matveyev A; Buck GA; Jefferson KK; Pepperell CS; Dillard JP
    mSphere; 2024 Jul; 9(7):e0045024. PubMed ID: 38926904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of recombinant single-chain antibodies neutralizing the cytolytic activity of vaginolysin, the main virulence factor of Gardnerella vaginalis.
    Pleckaityte M; Mistiniene E; Lasickiene R; Zvirblis G; Zvirbliene A
    BMC Biotechnol; 2011 Nov; 11():100. PubMed ID: 22047084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic CMP-Nonulosonates against Multidrug-Resistant
    Gulati S; Schoenhofen IC; Lindhout-Djukic T; Schur MJ; Landig CS; Saha S; Deng L; Lewis LA; Zheng B; Varki A; Ram S
    J Immunol; 2020 Jun; 204(12):3283-3295. PubMed ID: 32434942
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci.
    Gulati S; Cox A; Lewis LA; Michael FS; Li J; Boden R; Ram S; Rice PA
    Infect Immun; 2005 Nov; 73(11):7390-7. PubMed ID: 16239538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and phylogenetic characterization of Vaginolysin, the human-specific cytolysin from Gardnerella vaginalis.
    Gelber SE; Aguilar JL; Lewis KL; Ratner AJ
    J Bacteriol; 2008 Jun; 190(11):3896-903. PubMed ID: 18390664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.
    Ram S; Shaughnessy J; de Oliveira RB; Lewis LA; Gulati S; Rice PA
    Pathog Dis; 2017 Jun; 75(4):. PubMed ID: 28460033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility and vaginolysin in Gardnerella vaginalis from healthy and bacterial vaginosis diagnosed women.
    Knupp de Souza DM; Diniz CG; Filho DS; Andrade de Oliveira LM; Coelho DM; Talha LS; Nascimento TC; Ferreira-Machado AB; Silva VL
    J Infect Dev Ctries; 2016 Sep; 10(9):913-919. PubMed ID: 27694723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of Gardnerella vaginalis and Vaginolysin with the Apical versus Basolateral Face of a Three-Dimensional Model of Vaginal Epithelium.
    Garcia EM; Kraskauskiene V; Koblinski JE; Jefferson KK
    Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30692180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using an in-vitro biofilm model to assess the virulence potential of bacterial vaginosis or non-bacterial vaginosis Gardnerella vaginalis isolates.
    Castro J; Alves P; Sousa C; Cereija T; França Â; Jefferson KK; Cerca N
    Sci Rep; 2015 Jun; 5():11640. PubMed ID: 26113465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-based detection and inhibition of vaginolysin, the Gardnerella vaginalis cytolysin.
    Randis TM; Kulkarni R; Aguilar JL; Ratner AJ
    PLoS One; 2009; 4(4):e5207. PubMed ID: 19370149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaginolysin drives epithelial ultrastructural responses to Gardnerella vaginalis.
    Randis TM; Zaklama J; LaRocca TJ; Los FC; Lewis EL; Desai P; Rampersaud R; Amaral FE; Ratner AJ
    Infect Immun; 2013 Dec; 81(12):4544-50. PubMed ID: 24082080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between statin use, the vaginal microbiome, and Gardnerella vaginalis vaginolysin-mediated cytotoxicity.
    Abdelmaksoud AA; Girerd PH; Garcia EM; Brooks JP; Leftwich LM; Sheth NU; Bradley SP; Serrano MG; Fettweis JM; Huang B; Strauss JF; Buck GA; Jefferson KK
    PLoS One; 2017; 12(8):e0183765. PubMed ID: 28846702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence Comparison of Vaginolysin from Different
    Garcia EM; Serrano MG; Edupuganti L; Edwards DJ; Buck GA; Jefferson KK
    Pathogens; 2021 Jan; 10(2):. PubMed ID: 33498226
    [No Abstract]   [Full Text] [Related]  

  • 20. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae.
    Shaughnessy J; Gulati S; Agarwal S; Unemo M; Ohnishi M; Su XH; Monks BG; Visintin A; Madico G; Lewis LA; Golenbock DT; Reed GW; Rice PA; Ram S
    J Immunol; 2016 Feb; 196(4):1732-40. PubMed ID: 26773149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.